Structures by: Chi S. M.
Total: 16
1,1-Difluoro-3-phenyl-9-(pyridin-2-yl)-1<i>H</i>-1λ^4^,11λ^4^-1,3,5,2-oxadiazaborinino[3,4-<i>a</i>][1,8]naphthyridine
C20H13BF2N4O
IUCrData (2016) 1, 7 x161129
a=10.144(2)Å b=16.276(3)Å c=10.491(2)Å
α=90.00° β=101.27(3)° γ=90.00°
C19H20N6,2(ClO4)
C19H20N6,2(ClO4)
Dalton Transactions (2008) 47 6817-6824
a=8.1910(5)Å b=19.3250(12)Å c=27.8850(19)Å
α=90.00° β=90.00° γ=90.00°
C38H37Cl3N12O13Zn2
C38H37Cl3N12O13Zn2
Dalton Transactions (2008) 47 6817-6824
a=17.274(2)Å b=12.164(2)Å c=20.729(3)Å
α=90.00° β=94.612(2)° γ=90.00°
C50H52N12O14Zn4,CH2Cl2
C50H52N12O14Zn4,CH2Cl2
Dalton Transactions (2008) 47 6817-6824
a=18.411(2)Å b=8.6379(8)Å c=19.976(2)Å
α=90.00° β=109.311(2)° γ=90.00°
C58H60N12O20Zn5,4(O)
C58H60N12O20Zn5,4(O)
Dalton Transactions (2008) 47 6817-6824
a=23.643(3)Å b=8.9890(18)Å c=36.249(3)Å
α=90.00° β=100.896(2)° γ=90.00°
C31H29Cl3N6O
C31H29Cl3N6O
Dalton transactions (Cambridge, England : 2003) (2011) 40, 28 7365-7374
a=14.215(4)Å b=11.089(3)Å c=18.409(5)Å
α=90.00° β=101.018(4)° γ=90.00°
C49H42BCl3CuF4N6P
C49H42BCl3CuF4N6P
Dalton transactions (Cambridge, England : 2003) (2011) 40, 28 7365-7374
a=17.4863(17)Å b=17.5038(18)Å c=31.150(3)Å
α=90.00° β=99.520(2)° γ=90.00°
C46.23H36.43BCl3.52CuF4N6O0.33P
C46.23H36.43BCl3.52CuF4N6O0.33P
Dalton transactions (Cambridge, England : 2003) (2011) 40, 28 7365-7374
a=14.956(15)Å b=19.102(19)Å c=16.461(17)Å
α=90.00° β=100.210(17)° γ=90.00°
C52H34Cl2N16O14Pb2
C52H34Cl2N16O14Pb2
Dalton transactions (Cambridge, England : 2003) (2011) 40, 28 7365-7374
a=12.842(3)Å b=15.845(3)Å c=15.529(3)Å
α=90.00° β=90.22(3)° γ=90.00°
C28H21Cl3N6
C28H21Cl3N6
Dalton transactions (Cambridge, England : 2003) (2011) 40, 28 7365-7374
a=31.115(3)Å b=11.6709(15)Å c=16.466(2)Å
α=90.00° β=119.257(2)° γ=90.00°
C31H28Cl3N8O7.5Pb
C31H28Cl3N8O7.5Pb
Dalton transactions (Cambridge, England : 2003) (2011) 40, 28 7365-7374
a=9.8676(10)Å b=19.013(2)Å c=19.500(2)Å
α=90.00° β=93.953(2)° γ=90.00°
<i>N</i>-(7-Dibromomethyl-5-methyl-1,8-naphthyridin-2-yl)benzamide--pyrrolidine-2,5-dione (1/1)
C17H13Br2N3O1,C4H5NO2
Acta Crystallographica Section E (2017) 73, 1 1-3
a=9.6931(19)Å b=15.699(3)Å c=14.614(3)Å
α=90.00° β=108.99(3)° γ=90.00°
9-(Dibromomethyl)-1,1-difluoro-3,7-dimethyl-1<i>H</i>-[1,3,5,2]oxadiazaborinino[3,4-<i>a</i>][1,8]naphthyridin-11-ium-1-uide
C12H10BBr2F2N3O
Acta Crystallographica Section E (2016) 72, 11 1642-1644
a=17.161(3)Å b=7.2169(14)Å c=11.678(2)Å
α=90.00° β=90.00° γ=90.00°
4-Acetamidobenzoic acid monohydrate
C9H9NO3,H2O
Acta Crystallographica Section E (2014) 70, 11 o1154
a=6.6712(13)Å b=28.870(6)Å c=4.9920(10)Å
α=90.00° β=100.01(3)° γ=90.00°
<i>N</i>-(7-Dibromomethyl-5-methyl-1,8-naphthyridin-2-yl)acetamide-- pyrrolidine-2,5-dione (1/1)
C12H11Br2N3O,C4H5NO2
Acta Crystallographica Section E (2013) 69, 2 o153-o154
a=11.537(2)Å b=7.0093(14)Å c=11.632(2)Å
α=90.00° β=106.57(3)° γ=90.00°
<i>N</i>-(7-Methyl-1,8-naphthyridin-2-yl)acetamide--acetic acid (1/1)
C11H11N3O1,C2H4O2
Acta Crystallographica Section E (2013) 69, 4 o489
a=8.3628(17)Å b=9.0904(18)Å c=9.5093(19)Å
α=71.30(3)° β=76.43(3)° γ=78.64(3)°